AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04132375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.
Study NCT04132375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.
Study NCT00453960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genivis
Description: 54 mg/day daily for 6 months
Study NCT00453960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone Acetate
Description: tablets 10mg/day from day 16 to 25 of menstruation
Study NCT00453960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets daily for 6 months
Study NCT03190642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
Study NCT00973349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: 8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
Study NCT02609997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation
Description: The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
Study NCT02609997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation
Description: The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
Study NCT02609997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone
Description: All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
Study NCT02609997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscoelastic materials
Description: viscoelastic materials are used to protect corneal endothelial cells
Study NCT02609997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proparacaine
Description: 0.5% proparacaine (Alcaine, Alcon Laboratories)
Study NCT01677390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-75
Description: 1-2 mg/kg IV every 21 days
Study NCT01677390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 10 mg PO daily
Study NCT00812695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Gold standard treatment for Obstructive sleep apnea
Study NCT00667446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3 Month Depot
Study NCT00322153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine ER
Description: 28mg(7mg capsules) once daily and oral administration for 24 weeks.
Study NCT00322153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral administration once daily.
Study NCT01879540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aTIV
Description: Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
Study NCT02414139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib was administered orally, at a dose of 400 mg on a continuous twice daily dosing schedule.~Capmatinib was administered to participants in Cohorts 1a, 1b, 2, 3, 4, 5a and 5b in a fasted state. For Cohorts 6.1. 6.2 and 7, capmatinib was administered either with or without food.
Study NCT03277833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)
Description: Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
Study NCT03277833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, parallel design
Study NCT02951676 — intervention group
Intervention type: PROCEDURE
Intervention: Extraction
Description: Extraction of impacted third molar teeth
Study NCT00769665 — intervention group
Intervention type: OTHER
Intervention: Systane Ultra
Description: Re-wetting ocular eye drop
Study NCT00769665 — intervention group
Intervention type: OTHER
Intervention: Sensitive Eyes Rewetting Drops
Description: Re-wetting ocular eye drop
Study NCT01165567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarpogrelate
Description: sarpogrelate, 300mg/day,duration: 4 weeks
Study NCT02536833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Study NCT02536833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03612895 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
Study NCT00738517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immunoadsorption / Immunoglobulin substitution
Description: Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
Study NCT03954938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Craving Manipulation
Description: Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
Study NCT01800149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge Augmentation
Description: After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
Study NCT03949751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acne Crème Plus
Description: The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
Study NCT00059254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleic acid (OA)
Description: OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
Study NCT00059254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitic Acid (PA)
Description: PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
Study NCT01306708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
Study NCT03682822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Artificial rupture of membranes
Description: Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
Study NCT03682822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Artificial rupture of membranes
Description: Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
Study NCT02938741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human Thymoglobulin
Description: r-ATG 2.5MG/KG\*4days were used in the conditioning
Study NCT02938741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: r-ATG 2.5MG/KG\*4days were not used in the conditioning
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
Study NCT01010217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
Study NCT00535912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cells autograft
Description: Treatment by Intensive Chemotherapy and autograft
Study NCT01795066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
Study NCT02741180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D Imaging
Description: roadmapping of electrophysiology (EP) procedures
Study NCT02741180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Late Gadolinium Enhancement (LGE)
Description: useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
Study NCT02220998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily
Study NCT02220998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily
Study NCT02220998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT00945854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain cereal diet
Description: Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
Study NCT00945854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined cereal diet
Description: Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
Study NCT04188171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polidocanol foam sclerotherapy
Description: * Preparation of the foam is done according to the Tessari technique (2 disposable 20ml syringe, a three-way tap, reusable extender adapted to intravenous needle).~* Sclerosant applied according to the Blanchard technique through a disposable transparent anoscope (patient in knee-chest position).~* In each session, treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).~* During the intervention period the participants are observed at 3-week intervals. The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation.~* After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months.
Study NCT04231591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NT-proBNP
Description: Collect serum NT-proBNP levels in singleton ACHD patients and a comparative normotensive control group at time of admission for delivery to characterize negative predictive values for intrapartum and postpartum cardiac events.
Study NCT00321893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
Study NCT00321893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo twice daily for one year.
Study NCT04038632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decentralization of Childhood TB Diagnosis
Description: The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
Study NCT04204785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise Reduction Education
Description: OR staff will be offered education regarding the importance of minimizing noise in the OR. There will also be reminder signs and posters for the duration of the post-education period.
Study NCT02874768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h)
Study NCT02874768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h)
Study NCT01281527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: 50 - 150 mg eq. every 30 days
Study NCT03783247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
Study NCT03783247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca BLock
Description: In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
Study NCT01211587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safinamide
Description: Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
Study NCT01211587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
Study NCT01251471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg/d; optional 20 mg/d after 2 weeks.
Study NCT02526329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor regulatory T lymphocytes
Description: Given IV
Study NCT02526329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01627171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 10mg
Description: Given at the start of the bowel preparation the day before colonoscopy
Study NCT01627171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10mg
Description: Given at the start of the bowel preparation the day before colonoscopy
Study NCT01627171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethelene Glycol
Description: 280g reconstituted in 4 liters of water
Study NCT01627171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picosulfate sodium
Description: Two sachets, Each sachet has 10mg dose
Study NCT01357200 — intervention group
Intervention type: OTHER
Intervention: enteral formula
Description: Complete feeding of study enteral formula, route and regime prescribed by the physician.
Study NCT03227341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: 8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
Study NCT04109898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (I-gel) insertion
Description: Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
Study NCT04330820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: This study will investigate the combination of a fixed maximum venetoclax dose with increasing cytarabine doses plus mitoxantrone in a fixed dose in phase I. In Phase II cytarabine will be given at MDT or RP2D that assessed in phase I.~The venetoclax dose of 400 mg will be reached by a ramp up over 3 days. Parallel chemotherapy with cytarabine and mitoxantrone will start on day 3.
Study NCT04421807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapulatoracic stabilization exercises
Description: Scapulatoracic stabilization exercises consisted of 3 phases; the warming phase which consists of mobility and stretching; exercise phase consisting of static, dynamic and functional phase; the cooling phase consisting of mobility and stretching. Scapulatoracic stabilization exercises additionally applied to CDT were performed 3 days a week for 8 weeks. These exercises were specially planned for the patients and applied gradually
Study NCT04421807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy (CDT)
Description: In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.